Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3444526 | 0.99 | KDM4E (0.42) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL3867984 | 0.86 | HSD17B10 (0.46) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL3443894 | 0.85 | CYP2A6 (0.44) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL2385054 | 0.85 | MAPT (0.46) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL2382248 | 0.84 | MAPT (0.43) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL3867457 | 0.82 | KDM4E (0.41) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL2384414 | 0.82 | PADI4 (0.44) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL5739997 | 0.82 | KDM4E (0.41) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL2385267 | 0.82 | KDM4E (0.43) | KDM4EMAPTNPSR1APAF1PKM | |
| SCHEMBL2384375 | 0.81 | KDM4E (0.41) | KDM4EMAPTNPSR1APAF1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816368-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2010-10-19 | — | — | US | claimed |
| US-20090042924-A1 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | claimed |
| US-7456193-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-11-25 | — | — | US | claimed |
| EP-1556380-B1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2006-04-12 | — | — | EP | claimed |
| US-20050222192-A1 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | claimed |
| US-7816368-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2010-10-19 | — | — | US | disclosed |
| US-20090042924-A1 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| US-7456193-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-11-25 | — | — | US | disclosed |
| EP-1556380-B1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050222192-A1 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | disclosed |
| EP-1556380-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037821-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222192-A1 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | CBR3, PNPO, CBR1 | KDM4E 2222/4885MAPT 4161/4885NPSR1 1509/4885 |
| US-20090042924-A1 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics | PNPO, DPYD, PDXK | KDM4E 2743/4885MAPT 4064/4885NPSR1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.